drugset / Trial / NCT01550926

A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms

NCT01550926

Phase 1 Completed 48 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to determine whether a new dosage form and dose of orlistat is equivalent to the currently marketed form.

Timeline

Start
2009-02
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Orlistat Small molecule 60 mg
Comparator Orlistat Small molecule 120 mg

Indications